# US 2003/0207935 A1 · Novel optically active clausenamides, process of the preparation thereof, pharmaceutical composition containing the same and their medical use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0207935 A1
- Document ID: US20030207935A1
- Status: Published application
- Kind: A1
- Application number: 10/108,233
- Filed: 2002-03-26
- Published: 2003-11-06
- Earliest claimed: 2002-03-26
- Assignees: Institute of Materia Medica, Chinese Academy of Medical Sciences
- Inventors: Juntian Zhang; Liang Huang; Kemei Wu; Shiming Chen
- Web page: https://patentgrep.com/patent/US20030207935A1

## CPC

- C07D 207/273: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to some new optically active clausenamide derivatives, process of the preparation thereof, a pharmaceutical composition containing the same and their medical use, particularly their use in the respects of hypoxia protective, nootropic and neurodegenerative disease such as cerebral ischemia, Alzheimer disease and vascular dementia.

## Claims

### Claim 1

Levoclausenamide of formula I
15

### Claim 2

A optically active chiral compound of formula II,
16
wherein said derivative is selected from one of the following compounds:
3S4R5R6R (−) epiclausenamide,
3R4S5S6S (+)epiclausenamide,
3S4R5S6R (−)neoclausenamide,
3R4S5R6S (+)neoclausenamide,
3S4R5S6S(−)epineoclausenamide,
3R4S5R6R(+)epineoclausen amide,
3S4S5S6R (+)cisclausenamide,
3R4R5R6S (−)cisclausenamide,
3S4S5S6S (+)cisepiclausenamide,
3R4R5R6R (−)cisepiclausenamide,
3S4S5R6S (−)cisneoclausenamide,
3R4R5S6R (+)cisneoclausenamide,
3S4S5R6R(−)cisepineoclausenamide, and
3R4R5S6S(+)cisepineoclausen-amide.

### Claim 3

A pharmaceutical composition comprising an optically active compound of formula I and/or II and pharmaceutically carrier or excipient.

### Claim 4

A pharmaceutical composition for the prevention and/or treatment of comprising an optically active compound of formula I and/or II and pharmaceutically carrier or excipient.

### Claim 5

A use of an optically active compound of formula I and/or II for the manufacture of medicament for the perention and/or treatment of neurodegenerative disease such as cerebral ischemia, Alzheimer disease and vascular dementia.

### Claim 6

A method for the prvention and/or treatment of neurodegenerative disease comprising administrating to a patient suffered with neurodegenerative disease or high risk of neurodegenrative disease an effective prevention and/or treatment amount of an optically active compound of formula I and/or II.

### Claim 7

A use of an optically active compound of formula I and/or II for the manufacture of medicament for the prevention and/or treatment of neurodeganerative diseases.

### Claim 8

A process of the preparation of levoclausenamide, which characterized in that:
1. De novo synthesis by using intramoleuclar inductive asymmetrical Dargen reaction to prepare compound (2*);
17
2. Biocatalystic resolution of said compound (2*); or
3. Chemical resolution of the racemic clausenamidone of formula (5*)
18

### Claim 9

A process for preparaing an optical active clausenamide derivatives selected from the following compounds:
3S4R5R6R (−) epiclausenamide,
3R4S5S6S (+)epiclausenamide,
3S4R5S6R (−)neoclausenamide,
3R4S5R6S (+)neoclausenamide,
3S4R5S6S(−)epineoclausenamide,
3R4S5R6R(+)epineoclausen amide,
3S4S5S6R (+)cisclausenamide,
3R4R5R6S (−)cisclausenamide,
3S4S5S6S (+)cisepiclausenamide,
3R4R5R6R (−)cisepiclausenamide,
3S4S5R6S (−)cisneoclausenamide,
3R4R5S6R (+)cisneoclausenamide,
3S4S5R6R(−)cisepineoclausenamide, and
3R4R5S6S(+)cisepineoclausen-amide,
said process is shown in scheme 4
19
Note:
(i)base catalyzed cyclization, NaOCH3 or (CH3)4NOH
(j)resolution, resolving agent (−)menthyoxyl acetyl chloride
(k) derivation of C3—OH by dihydropyan or acetylchloride/pyridine
(l)reduction of C6═O by reducing agent NaBH4 or 1-selectride
(m) reduction of C6═O by reducing agent Al(i-C3H7O)3
(n) oxidation of C3—OH by oxidizing agent, K2Cr2O7/H+, or KmnO4+CuSO4, MnO2 or DMSO/(COCl)2
(o) reduction of 2,3 by NaBH4/H+, or NaBH4/AlCl3, or catalytic hydrogenation
(p) invertion of C3—OH by DIAD or DEAD/TPP, H+(mitsunobu method) or by CsOAc/18-crown-8, or
said process is shown in scheme 5 wherein starting compound from a know compound racemic 3-deoxyepiclausenamide:
20
